3:00 PM Registration
4:00 - 4:30 Welcome and Overview of Program
Phyllis Tien, MD, Kenneth E. Sherman, MD, PhD
Session 1 HIV and Liver Disease: The Evolving Landscape
Moderator: Kenneth Sherman, MD, PhD
4:30 – 5:00 Breaking News in HIV
John Brooks, MD
5:00 – 5:30 Hot Topics in Liver Disease in 2025: HIV Considerations
Phyllis Tien, MD
5:30 – 6:00 NIH Goals and Opportunities
Josh Radke, PhD
6:00 – 6:30 ESI Abstract: Higher Plasma Kynurenine - Tryptophan Ratio Predicts Incident Hepatic Fibrosis in Women with HIV
Maria Duarte, MD, University of California, San Francisco
6:30 – 6:45 Panel Discussion
6:45 – 7:00 Break
7:00 – 9:00 Poster Reception (all poster presenters at posters)
Friday, September 26
(agenda subject to change)
7:30 - 9:00 AM Continental Breakfast
Session 2 Emerging Issues in Metabolic Dysfunction Associated Steatotic Liver Disease in HIV
Moderator: Phyllis Tien, MD
8:00 - 8:30 Steatotic Liver Disease: What does it mean for PWH?
Jennifer Price, MD, PhD
8:30 – 9:00 Adipocyte Function and MASLD
Jordan Lake, MD, MSc
9:00 – 9:30 Noninvasive Testing to Guide Therapy for Liver Disease
Richard Sterling, MD
9:30 - 9:45 ESI Abstract: Predictors of Incident Hepatic Fibrosis and Steatotic Liver Disease -
Associated Fibrosis Among Women with and without HIV
Maria Duarte, MD
9:45 - 10:00 ESI Abstract: Radiographic Findings of Steatotic Liver Disease are Associated with
Increased Risk of End-Stage Liver Disease Among People With and Without HIV Infection
Jessie Torgerson, MD
10:00 - 10:15 Panel Discussion
10:15 - 10:45 Break
Session 3 Advances in HBV Pathogenesis, Prevention, and Treatment
Moderator: David Thomas, MD, MPH
10:45 – 11:15 HBV DNA Reservoirs and Achieving HBV Cure
Ashwin Balagopal, MD
11:15 – 11:45 Immune and Non-Immune Targets of HBV: Does Single or Combination Therapy Make Sense?
Shyamasundaran Kottilil, MD, PhD
11:45 – 12:15 HBV Prevention: Optimizing Primary and Secondary Vaccine Strategies
Kenneth E. Sherman, MD, PhD
12:15 – 12:30 Trainee Abstract: Effect of HCV Clearance on Immunosenescence in HIV/HCV Coinfection: Evaluating Changes in Senescence-Associated Secretory Phenotype (SASP) Biomarkers
Alexandra Willauer, MD
12:30 – 12:45 Panel Discussion
12:45 – 1:15 Break
1:15 – 2:15 Lunch Discussion sponsored by Madrigal Pharmaceuticals
Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra
Pierre Gholam, MD - University Hospitals Cleveland Medical Center
6:30 - 8:30 Faculty Dinner (Invite Only)
Saturday, September 27
(agenda subject to change)
7:30 - 9:00 AM Continental Breakfast
Session 4 Emerging Issues in Viral Hepatitis and Liver Fibrosis
Phyllis Tien, MD
8:00 - 8:30 HCV Prevention and Long-Acting Therapies
David Thomas, MD, MPH
8:30 - 9:00 Updates in Hepatitis E Virus
Kenneth E. Sherman, MD, PhD
9:00 - 9:30 Omic Approaches to Understanding Liver Fibrosis
Brad E Aouizerat, MS, PhD
9:30 - 9:45 Trainee Abstract: The Last Mile: Understanding Barriers to Hepatitis C Virus (HCV) Micro- Elimination among People with HIV (PWH) in San Francisco, 2021-2024
Grace Haser, MD
9:45 - 10:00 Abstract: The Gut Microbiome Links Bacterial Amino Acid Synthesis to Hepatic Steatosis in People with HIV
Curtis Gabriel, MD
10:00 - 10:15 Panel Discussion
10:15 - 10:45 Break
Session 5 Trends in Alcohol, Drugs, and Polysubstance Use and Impacts on HIV and Viral Hepatitis Infections
Moderator: David Thomas, MD, MPH
10:45 - 11:15 Unhealthy Alcohol Use Among Patients in HIV: Can We Change the Outcome?
Judy Hahn, PhD
11:15 - 11:45 Emerging Issues in Substance Use in the US: Impacts on HIV and Viral Hepatitis
Kim Page, PhD
11:45 - 12:15 Managing the Opioid Epidemic
12:15 - 12:30 Panel Discussion
Session 6 Research Agenda - Plans for the Next Two Years
Moderator: Kenneth E. Sherman, MD, PhD
12:30 - 1:00 Summary of Key Research Agenda/Plans for the Next 2 Years
Phyllis Tien, MD
1:00 - 1:15 Conference Wrap-Up and Boxed Lunch To-Go
Phyllis Tien, MD
6:00 - 8:00 All Attendee Dinner
